ReNeuron announces the appointment of Allenby Capital as the Company's Nominated Adviser and Sole Broker, with immediate effect. reneuron.com/investors/rns-…

$RENE ReNeuron appoints new scientific advisory board tinyurl.com/2qdqeyd5 @reneuronplc $RNUGF #RENE #RNUGF

.ReNeuron Group plc announces its newly established Scientific Advisory Board: 👨‍🔬Prof. Giuseppe (Beppe) Battaglia 👩‍🔬Prof. Edit I Buzás 👨‍🔬Prof. Dr. rer. Nat. Bernd Giebel 👨‍🔬Prof. Kenneth W. Witwer 👨‍🔬Prof. Stefano Pluchino (chair) For more information, bit.ly/40CWDSJ #RENE

ReNeuron announces the appointment of its newly established Scientific Advisory Board, chaired by Prof. Stefano Pluchino. Details of the Board members and their bios can be found on the Company website here: reneuron.com/about-us/advis…

Join RENEURON GROUP PLC's Preliminary Results for the year ended 31 March 2023 on 25th May 2023 at 9:30am BST, Click below to register. #RENE ReNeuronPLC investormeetcompany.com/reneuron-group…

ReNeuron Group plc (AIM: #RENE, ReNeuron Group plc) Notice of Results 📅Thursday 25 May 2023 🎦Investor presentation via Investor Meet Company at 9.30am BST 🔗bit.ly/45cb7vp

ReNeuron will announce its preliminary results for the year ended 31 March 2023 on Thursday 25 May Management will also be hosting a live online presentation relating to the results via the Investor Meet Company at 9:30am BST on Thursday 25 May 2023. investormeetcompany.com/reneuron-group…

ReNeuron Group (AIM: #RENE, ReNeuron Group plc) Preliminary results 💰Revenue of £0.5m 💷Cash of £7.2m, runway into 2024 👉Reduced operating costs 👉Reduced loss for the year 🔗shorturl.at/lrvNO THREAD⤵️

$RENE ReNeuron reports increase in revenue after a transitional year tinyurl.com/2kf2mjx4 @reneuronplc $RNUGF #RENE #RNUGF

ReNeuron announces its unaudited preliminary results for the year ended 31 March 2023. Read the full announcement here: reneuron.com/investors/rns-… #RENE

ReNeuron Group plc — Full steam ahead with CustomEx. $RENE #AIM London Stock Exchange #healthcare #equityresearch hubs.ly/Q01Sdtp60

The Annual Report and Accounts for the year ended 31 March 2023 has today been sent to shareholders and is available to download on the Company’s website here: reneuron.com/investors/fina…

$RENE ReNeuron highlights exosome platform R&D progress tinyurl.com/2dcys3q7 @reneuronplc $RNUGF #RENE #RNUGF

ReNeuron Group (AIM: #RENE, ReNeuron Group plc) R&D Update 💼Creating a valuable/differentiated exosome delivery platform 📜in vivo data generated underlines value proposition 🔗londonstockexchange.com/news-article/R…

ReNeuron announces that it has successfully generated in vivo data to exemplify the cellular and tissue targeting capabilities of exosomes produced from its multiple conditionally immortalised producer cell lines. Read the full announcement here: reneuron.com/investors/rns-…

ReNeuron Group plc — A step forward on the Exosome delivery platform. $RENE #AIM ow.ly/NtNl50PLVt1

$RENE ReNeuron to showcase drug delivery platform at Cell2023 tinyurl.com/ykeh8vpe @reneuronplc $RNUGF #RENE #RNUGF

ReNeuron announces that Dr Samantha Thomas will be presenting in vivo data exemplifying the cellular and tissue targeting capabilities and highlighting the significant advantages of ReNeuron’s CustomEX™ drug delivery platform, at #Cell2023 in London: reneuron.com/investors/rns-…

ReNeuron announces its unaudited interim results for the six months ended 30 Sept 2023. Read the full announcement here: reneuron.com/investors/rns-…

ReNeuron Group — H124 results reaffirm focus on CustomEX. $RENE #AIM ReNeuron Group plc ow.ly/uH7f50Qbphq